statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Posters to be presented highlighting research investigating pegtibatinase as the first potential disease-modifying treatment for classical homocystinuriaSAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE...

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the fifteen ratings firms that are covering the company, Marketbeat Ratings...

Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Upcoming data presentations underscore the potential for FILSPARI to become a foundational treatment for IgAN and Travere's leadership and commitment to innovation in rare kidney disease (RKD)SAN...

Travere Therapeutics to Present Abstracts on FILSPARI  (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association

This indicator may be signaling that TVTX's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Travere Therapeutics (TVTX, $7.33) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

This is a Bearish indicator signaling TVTX's price could decline from here. Traders may explore shorting the stock or put options...

Travere Therapeutics (TVTX, $7.33) Moving Average Convergence Divergence (MACD) Histogram turned negative on April 1, 2024

Guggenheim reaffirmed their neutral rating on shares of Travere Therapeutics (NASDAQ:TVTX - Free Report) in a research note released on Wednesday morning, MarketBeat Ratings reports. A number of...

Guggenheim Reaffirms "Neutral" Rating for Travere Therapeutics (NASDAQ:TVTX)

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX  Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $7.57, but opened at $7.11. Travere...

Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down to $7.57

This is a Bullish indicator signaling TVTX's price could rise from here. Traders may explore going long the stock or buying call options...

Travere Therapeutics (TVTX, $7.67) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 27, 2024

Oak Ridge Investments LLC reduced its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX  Free Report) by 21.7% in the 4th quarter, according to its most recent disclosure with the...

Oak Ridge Investments LLC Cuts Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Travere Therapeutics (TVTX, $7.87) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 22, 2024

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Volume	5,303.00
52-Wk High	$22.75
52-Wk Low	$5.25

TVTX Travere Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals